Sep 15 2009
HUYA Bioscience International, the leader in global pharmaceutical co-development with China, today announced a strategic partnership agreement with Guangzhou Institutes of Biomedicine and Health, Chinese Academy of Sciences (GIBH). HUYA has established a series of strategic partnerships with Chinese science institutes that affords it the opportunity to expand its portfolio of novel biopharmaceutical products. The agreement with GIBH provides HUYA the exclusive right of first review and negotiation for the licensing and development of certain novel compounds owned or controlled by GIBH.
Over the past four years, HUYA has established extensive collaborations with Chinese academic and commercial biopharmaceutical organizations to speed the development and value creation in worldwide markets for China-sourced product candidates. HUYA has entered into strategic partnerships with many institutions, including Shenyang Pharmaceutical University and the Beijing Institute of Material Medica.
"HUYA continues to be on the forefront of creating partnerships with leading Chinese institutions such as GIBH that will lead to the accelerated development of novel therapeutics," said Dr. Mireille Gingras, HUYA's CEO. "GIBH is an important pharmaceutical R&D institute in South China, and we are excited to partner with this regional leader to identify and pursue novel product opportunities."
Global leaders gather at the NFCR Summit to drive breakthroughs in cancer care